Diabetes Metab J.  2017 Jun;41(3):160-167. 10.4093/dmj.2017.41.3.160.

Diabetes Prevention in Australia: 10 Years Results and Experience

• Dunbar JA

• KMID: 2392489
• DOI: http://doi.org/10.4093/dmj.2017.41.3.160

Abstract

Clinical trials have demonstrated the efficacy of lifestyle modification for the prevention of type 2 diabetes mellitus but it was achieved at higher cost than can be sustained in routine health services. The first clinical trial to report was the Finnish Diabetes Prevention Study. This paper describes how Australia worked with Finnish colleagues to adapt the findings of that study to achieve a statewide diabetes prevention program. Small evaluative, effectiveness trials have been conducted in a number of countries to see if the results of the clinical trials can be replicated in routine health services. The Australian evaluative trial, Greater Green Triangle Diabetes Prevention Program is described in detail to demonstrate the ingredients for success in moving a program from one country to another. Few countries have managed to scale up from evaluative trials to statewide or national programs. The Australian experience is described in detail including lessons learned about what reduced the effectiveness, particularly the need for policy makers in government, people from the implementing organisation and researchers to work together from the start of the evaluative trial and throughout the first 5 years of a national program.

Keyword

Clinical trial; Diabetes mellitus, type 2; Diet; Evaluation studies; Government programs; Group processes; Life style; Policy

MeSH Terms

Administrative Personnel
Australia*
Diabetes Mellitus, Type 2
Diet
Government Programs
Group Processes
Health Services
Humans
Life Style

Reference

1. Shaw JE, Chisholm DJ. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust. 2003; 179:379–383.

2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047–1053.

3. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006; 333:475–480.

4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343–1350.

5. Lindstrom J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinanen-Kiukaanniemi S, Uusitupa M, Tuomilehto J. Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013; 56:284–293.

6. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20:537–544.

7. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393–403.

8. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368:1096–1105.

9. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005; 54:1150–1156.

10. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366:1279–1289.

11. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006; 368:1673–1679.

12. Absetz P, Valve R, Oldenburg B, Heinonen H, Nissinen A, Fogelholm M, Ilvesmaki V, Talja M, Uutela A. Type 2 diabetes prevention in the “real world”: one-year results of the GOAL implementation trial. Diabetes Care. 2007; 30:2465–2470.

13. Conner M, Norman P. Chapter 7, Self-efficacy and health behaviors. Predicting health behaviour: research and practice with social cognition models. Buckingham: Open University Press;1996. p. 163–196.

14. Laatikainen T, Dunbar JA, Chapman A, Kilkkinen A, Vartiainen E, Heistaro S, Philpot B, Absetz P, Bunker S, O'Neil A, Reddy P, Best JD, Janus ED. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health. 2007; 7:249.

15. Laatikainen T, Philpot B, Hankonen N, Sippola R, Dunbar JA, Absetz P, Reddy P, Davis-Lameloise N, Vartiainen E. Predicting changes in lifestyle and clinical outcomes in preventing diabetes: the Greater Green Triangle Diabetes Prevention Project. Prev Med. 2012; 54:157–161.

16. Schwarzer R. The Health Action Process Approach (HAPA). cited 2016 Dec 9. Available from: http://userpage.fu-berlin.de/health/hapa.htm.

17. Amundson HA, Butcher MK, Gohdes D, Hall TO, Harwell TS, Helgerson SD, Vanderwood KK. Montana Cardiovascular Disease and Diabetes Prevention Program Workgroup. Translating the diabetes prevention program into practice in the general community: findings from the Montana Cardiovascular Disease and Diabetes Prevention Program. Diabetes Educ. 2009; 35:209–220.

18. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med. 2008; 35:357–363.

19. Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Piatt GA. Translating the Diabetes Prevention Program into an urban medically underserved community: a nonrandomized prospective intervention study. Diabetes Care. 2008; 31:684–689.

20. Greaves C, Gillison F, Stathi A, Bennett P, Reddy P, Dunbar J, Perry R, Messom D, Chandler R, Francis M, Davis M, Green C, Evans P, Taylor G. Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular risk. Int J Behav Nutr Phys Act. 2015; 12:1.

21. Colagiuri S, Vita P, Cardona-Morrell M, Singh MF, Farrell L, Milat A, Haas M, Bauman A. The Sydney Diabetes Prevention Program: a community-based translational study. BMC Public Health. 2010; 10:328.

22. Schwarz P, Reddy P, Greaves C, Dunbar J, Schwarz J. Diabetes prevention in practice. Dresden: TUMAINI Institute for Prevention Management;2010.

23. Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, Khunti K. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care. 2014; 37:922–933.

24. Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, Vanhala M, Saltevo J, Niskanen L, Oksa H, Korpi-Hyovalti E, Tuomilehto J. FIN-D2D Study Group. National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health. 2007; 66:101–112.

25. Dunbar JA, Jayawardena A, Johnson G, Roger K, Timoshanko A, Versace VL, Shill J, Philpot B, Vartiainen E, Laatikainen T, Best JD, Janus ED. Scaling up diabetes prevention in Victoria, Australia: policy development, implementation, and evaluation. Diabetes Care. 2014; 37:934–942.

26. Dunbar JA, Hernan AL, Janus ED, Vartiainen E, Laatikainen T, Versace VL, Reynolds J, Best JD, Skinner TC, O'Reilly SL, Mc Namara KP, Stewart E, Coates M, Bennett CM, Carter R. Challenges of diabetes prevention in the real world: results and lessons from the Melbourne Diabetes Prevention Study. BMJ Open Diabetes Res Care. 2015; 3:e000131.

27. Centers for Disease Control and Prevention. National Diabetes Prevention Program. cited 2016 Dec 5. Available from: https://www.cdc.gov/diabetes/prevention/index.html.

28. NHS England. NHS Diabetes Prevention Programme. cited 2016 Dec 5. Available from: https://www.england.nhs.uk/ourwork/qual-clin-lead/diabetes-prevention/.

29. Glasgow RE, Klesges LM, Dzewaltowski DA, Bull SS, Estabrooks P. The future of health behavior change research: what is needed to improve translation of research into health promotion practice? Ann Behav Med. 2004; 27:3–12.

30. O'Reilly SL, Dunbar JA, Versace V, Janus E, Best JD, Carter R, Oats JJ, Skinner T, Ackland M, Phillips PA, Ebeling PR, Reynolds J, Shih ST, Hagger V, Coates M, Wildey C. MAGDA Study Group. Mothers after Gestational Diabetes in Australia (MAGDA): a randomised controlled trial of a postnatal diabetes prevention program. PLoS Med. 2016; 13:e1002092.

31. McNamara K, Philpot B, Janus ED, Dunbar JA. Greater Green Triangle Diabetes Prevention Program: remaining treatment gaps in hypertension and dyslipidaemia. Aust J Rural Health. 2010; 18:43–44.

32. Pressman JK, Wildavsky AB. Implementation. Berkeley: University of California Press;1984.

33. Life Program Referral Pathway. Patient eligibility and referral pathway. cited 2016 Dec 5. Available from: http://www.lifeprogram.org.au/images/Referral_pathway_GP_Case_Finding_Agreement.pdf.

34. Simmons RK, Harding AH, Jakes RW, Welch A, Wareham NJ, Griffin SJ. How much might achievement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented at the population level? Diabetologia. 2006; 49:905–911.

35. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007; 334:299.

36. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008; 336:1180–1185.

37. Vos T. University of Queensland. Centre for Burden of Disease and Cost-Effectiveness; Deakin University Population Health. Assessing cost-effectiveness in prevention (ACE-Prevention): final report. Brisbane: Centre for Burden of Disease and Cost-Effectiveness, School of Population Health, University of Queensland;2010.